344 related articles for article (PubMed ID: 25673639)
21. Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies.
Atiq F; Blok R; van Kwawegen CB; Doherty D; Lavin M; van der Bom JG; O'Connell NM; de Meris J; Ryan K; Schols SEM; Byrne M; Heubel-Moenen FCJI; van Galen KPM; Preston RJS; Cnossen MH; Fijnvandraat K; Baker RI; Meijer K; James P; Di Paola J; Eikenboom J; Leebeek FWG; O'Donnell JS
Blood; 2024 Apr; 143(14):1414-1424. PubMed ID: 38142407
[TBL] [Abstract][Full Text] [Related]
22. Acquired von Willebrand syndrome: von Willebrand factor propeptide to von Willebrand factor antigen ratio predicts remission status.
Lee A; Sinclair G; Valentine K; James P; Poon MC
Blood; 2014 Jul; 124(5):e1-3. PubMed ID: 24951428
[TBL] [Abstract][Full Text] [Related]
23. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
Michiels JJ; van Vliet HH
Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
[TBL] [Abstract][Full Text] [Related]
24. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease.
de Wee EM; Sanders YV; Mauser-Bunschoten EP; van der Bom JG; Degenaar-Dujardin ME; Eikenboom J; de Goede-Bolder A; Laros-van Gorkom BA; Meijer K; Hamulyák K; Nijziel MR; Fijnvandraat K; Leebeek FW;
Thromb Haemost; 2012 Oct; 108(4):683-92. PubMed ID: 22918553
[TBL] [Abstract][Full Text] [Related]
25. Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease.
Atiq F; Meijer K; Eikenboom J; Fijnvandraat K; Mauser-Bunschoten EP; van Galen KPM; Nijziel MR; Ypma PF; de Meris J; Laros-van Gorkom BAP; van der Bom JG; de Maat MP; Cnossen MH; Leebeek FWG;
Br J Haematol; 2018 Jul; 182(1):93-105. PubMed ID: 29767844
[TBL] [Abstract][Full Text] [Related]
26. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
[TBL] [Abstract][Full Text] [Related]
27. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
[TBL] [Abstract][Full Text] [Related]
28. CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease.
Sanders YV; van der Bom JG; Isaacs A; Cnossen MH; de Maat MP; Laros-van Gorkom BA; Fijnvandraat K; Meijer K; van Duijn CM; Mauser-Bunschoten EP; Eikenboom J; Leebeek FW;
J Thromb Haemost; 2015 Jun; 13(6):956-66. PubMed ID: 25832887
[TBL] [Abstract][Full Text] [Related]
29. Molecular genetics of type 2 von Willebrand disease.
Fressinaud E; Mazurier C; Meyer D
Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
[TBL] [Abstract][Full Text] [Related]
30. von Willebrand factor propeptide missense variants affect anterograde transport to Golgi resulting in ER retention.
Yadegari H; Biswas A; Ahmed S; Naz A; Oldenburg J
Hum Mutat; 2021 Jun; 42(6):731-744. PubMed ID: 33942438
[TBL] [Abstract][Full Text] [Related]
31. An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant.
Casonato A; Sartorello F; Cattini MG; Pontara E; Soldera C; Bertomoro A; Girolami A
Blood; 2003 Jan; 101(1):151-6. PubMed ID: 12393698
[TBL] [Abstract][Full Text] [Related]
32. Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman program.
Christopherson PA; Haberichter SL; Flood VH; Perry CL; Sadler BE; Bellissimo DB; Di Paola J; Montgomery RR;
J Thromb Haemost; 2022 Jul; 20(7):1576-1588. PubMed ID: 35343054
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.
Boylan B; Rice AS; De Staercke C; Eyster ME; Yaish HM; Knoll CM; Bean CJ; Miller CH;
J Thromb Haemost; 2015 Jun; 13(6):1036-42. PubMed ID: 25780857
[TBL] [Abstract][Full Text] [Related]
34. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van Vliet HH
Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353
[TBL] [Abstract][Full Text] [Related]
35. Current and emerging approaches for assessing von Willebrand disease in 2016.
Federici AB
Int J Lab Hematol; 2016 May; 38 Suppl 1():41-9. PubMed ID: 27426859
[TBL] [Abstract][Full Text] [Related]
36. Clinically relevant differences between assays for von Willebrand factor activity.
Boender J; Eikenboom J; van der Bom JG; Meijer K; de Meris J; Fijnvandraat K; Cnossen MH; Laros-van Gorkom BAP; van Heerde WL; Mauser-Bunschoten EP; de Maat MPM; Leebeek FWG;
J Thromb Haemost; 2018 Dec; 16(12):2413-2424. PubMed ID: 30358069
[TBL] [Abstract][Full Text] [Related]
37. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance.
Castaman G; Tosetto A; Federici AB; Rodeghiero F
Thromb Haemost; 2011 Apr; 105(4):647-54. PubMed ID: 21264446
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a novel mutation in the von Willebrand factor propeptide in a distinct subtype of recessive von Willebrand disease.
Lanke E; Kristoffersson AC; Philips M; Holmberg L; Lethagen S
Thromb Haemost; 2008 Aug; 100(2):211-6. PubMed ID: 18690339
[TBL] [Abstract][Full Text] [Related]
39. Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population.
Ogiwara K; Swystun LL; Paine AS; Kepa S; Choi SJ; Rejtö J; Hopman W; Pabinger I; Lillicrap D
J Thromb Haemost; 2021 Mar; 19(3):654-663. PubMed ID: 33219619
[TBL] [Abstract][Full Text] [Related]
40. Next-generation sequencing of von Willebrand factor and coagulation factor VIII genes: a cross-sectional study in Croatian adult patients diagnosed with von Willebrand disease.
Lapić I; Radić Antolic M; Boban A; Coen Herak D; Rogić D; Zadro R
Croat Med J; 2022 Apr; 63(2):166-175. PubMed ID: 35505650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
